2,670
Views
59
CrossRef citations to date
0
Altmetric
Report

New methods allowing the detection of protein aggregates

A case study on trastuzumab

, , , &
Pages 142-150 | Received 03 Nov 2008, Accepted 11 Dec 2008, Published online: 01 Mar 2009

References

  • Volkin DB, Mach H, Middaugh CR. Shirley BA. Degradative covalent reactions important to protein stability. Methods in Molecular Biology, Vol. 40: Protein Stability and Folding: Theory and Practice 1995; Totowa, NJ Humana Press Inc 35 - 63
  • Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 2003; 20:1325 - 1336
  • Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000; 203:1 - 60
  • Chi EY, Weickmann J, Carpenter JF, Manning MC, Randolph TW. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 2005; 94:256 - 274
  • Webb SD, Cleland JL, Carpenter JF, Randolph TW. A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20. J Pharm Sci 2002; 91:543 - 558
  • Carpenter JF, Kendrick BS, Chang BS, Manning MC, Randolph TW. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol 1999; 309:236 - 255
  • Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 2005; 289:1 - 30
  • Trastuzumab Product Approval Information—Licensing Action 2008 http://www.fda.gov/cder/biologics/products/trasgen092598.htm
  • Cudd A, Arvinte T, Das RE, Chinni C, MacIntyre I. Enhanced potency of human calcitonin when fibrillation is avoided. J Pharm Sci 1995; 84:717 - 719
  • Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002; 416:507 - 511
  • Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004; 21:897 - 903
  • Walsh G. Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol 2005; 23:553 - 558
  • Lawrence S. The biotech drug market. Nat Biotechnol 2004; 22:1496
  • European Public Assessment Report for authorised medicinal products for human use—Herceptin 2008 http://www.emea.europa.eu/humandocs/Humans/EPAR/herceptin/herceptin.htm
  • Demeester J, De Smedt SS, Sanders NN, Haustraete J. Jiskoot W, Crommelin DJ. Light scattering. Methods for structural analysis of protein pharmaceuticals 2005; Arlington, VA AAPS Press 245 - 275
  • Tessier PM, Lenhoff AM. Measurements of protein self-association as a guide to crystallization. Curr Opin Biotechnol 2003; 14:512 - 516
  • Bajaj H, Sharma VK, Kalonia DS. Determination of second virial coefficient of proteins using a dual-detector cell for simultaneous measurement of scattered light intensity and concentration in SEC-HPLC. Biophys J 2004; 87:4048 - 4055
  • Lakowicz JR. Time-domain lifetime measurements. Principles of Fluorescence Spectroscopy 1999; Second edition New York Kluwer Academic/Plenum Publishers 95 - 140
  • Ingle JD, Crouch SR. Ingle JD, Crouch SR. Molecular scattering methods. Spectrochemical analysis 1988; Upper Saddle River Prentice-Hall 494 - 524
  • Gabellieri E, Strambini GB. ANS fluorescence detects widespread perturbations of protein tertiary structure in ice. Biophys J 2006; 90:3239 - 3245
  • Hawe A, Sutter M, Jiskoot W. Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res 2008; 25:1487 - 1499
  • Demeule B, Gurny R, Arvinte T. Detection and characterization of protein aggregates by fluorescence microscopy. Int J Pharm 2007; 329:37 - 45
  • Arvinte T. Jiskoot W, Crommelin DJ. Analytical methods for protein formulations. Methods for structural analysis of protein pharmaceuticals 2005; Arlington, VA AAPS Press 661 - 666
  • Gabrielson JP, Brader ML, Pekar AH, Mathis KB, Winter G, Carpenter JF, et al. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci 2007; 96:268 - 279
  • Liu J, Andya JD, Shire SJ. A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. AAPS J 2006; 8:580 - 589

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.